Smith & Nephew Plc
23 January 2004
SMITH & NEPHEW ACQUIRES WOUND
DEBRIDER FROM HYDROCISION INC
23 January 2004
London, England and Andover, Massachusetts, January 23, 2004 - Smith & Nephew
plc (LSE:SN, NYSE:SNN) today announced that its Advanced Wound Management
business has acquired the VERSAJET surgical debridement product from HydroCision
Inc to add to its growing range of advanced wound bed preparation products.
VERSAJET is a specialised fluid jet instrument enabling surgeons to easily
remove damaged tissue and contaminants from surgical, traumatic and chronic
wounds in a precise and safe manner. Approved for use in the United States,
Canada and the European Union, VERSAJET was launched in 2003.
Smith & Nephew will acquire the VERSAJET product line for $5m, with additional
consideration payable upon reaching future development and sales milestones.
Smith & Nephew expects 2004 sales of the product to reach $2-3m.
'VERSAJET is an outstanding new technology that enables the clinician to
remove contamination and dead or decaying tissue when preparing wounds for
closure or healing,' said Jim Dick, President of the Advanced Wound
Management business of Smith & Nephew. 'VERSAJET is easy to use and will
strengthen our position in the rapidly growing wound bed preparation market.'
Doug Daniels, President and CEO of HydroCision, added: 'We are pleased that
Smith & Nephew has recognised the potential value of the fluid jet technology in
the field of wound care. As a leader in the advanced wound management field,
Smith & Nephew is well positioned to use the fluid jet technology to help
improve patient outcomes worldwide.'
About Smith & Nephew
Smith & Nephew (www.smith-nephew.com) is one of the world's leading medical
device companies, specialising in Orthopaedics, Endoscopy and Advanced Wound
Management products. Smith & Nephew ranks as the global leader in advanced
wound management and arthroscopy products and is the fastest growing full-line
orthopaedics company in the world.
Smith & Nephew's Advanced Wound Management business provides the leading range
of treatments for difficult to heal wounds. It develops innovative new
solutions to heal chronic and acute wounds, delivering excellent and cost
effective outcomes. The company has the world's leading advanced wound
management sales force and provides clinicians with a full range of education
programmes.
About HydroCision Inc.
Andover, Massachusetts, based HydroCision is the leading developer, manufacturer
and marketer of fluid jet-based surgical tools that are the foundation of a new
surgical modality - 'hydrosurgery'. Hydrosurgery improves patient care by
selectively removing tissue, minimizing collateral damage and bleeding and
promoting the healing process. More information on the company is available at
www.hydrocision.com.
Enquiries:
Smith & Nephew
Healthcare Media
Jim Dick +44 148 222 5181 (UK)
Smith & Nephew Wound Management
Smith & Nephew
Financial Media and Investors
Angie Craig +44 20 7401 7646 (UK)
Smith & Nephew Corporate Affairs Director +1 212 850 5756 (US)
HydroCision Inc
Doug Daniels +1 978 474 9300 (US)
President and CEO
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.